Breaking: Asset Sale Deal Ignites Avalo Therapeutics
- September 12th, 2023
- 585 views
Shares of Avalo Therapeutics, Inc. (Nasdaq: AVTX) surged by more than 40% following the company's announcement of a purchase agreement with AUG Therapeutics, LLC (AUG), wherein it will sell its rights, assets, and interests related to the 800 Series compounds — AVTX-801 (D-galactose), AVTX-802 (D-mannose), and AVTX-803 (L-fucose) -.
As part of the deal, AUG will provide an upfront payment of $150,000 and may make contingent milestone payments of up to $45 million upon FDA approval, excluding Rare Pediatric Disease indications. Additionally, AUG will assume certain liabilities and all costs associated with the 800 Series. The transaction is anticipated to close in Q4 2023, subject to customary conditions.
Avalo Therapeutics anticipates that this move will immediately boost its cash flow and reduce resource utilization for non-core assets, while still holding significant potential for the company upon program success.
In pre-market, $AVTX was trading at $0.13, marking a notable gain of $0.04 (+54.06%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
FTC Takes Action to Prevent Anticompetitive Arrangement in Beretta, Ruger Deal
September 16th, 2026Why Opponent Preparation Matters for Post-Graduate Athletes
September 16th, 2026The Work Behind the Game: How Football Teams Prepare to Compete
September 15th, 2026NJCP Operates on a Prep Model Built Around a Full Season
September 14th, 2026Earnings Preview: High Tide, Kestra Medical, and RF Industries in Focus
September 12th, 2026
Member Login